PL376756A1 - Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych - Google Patents

Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych

Info

Publication number
PL376756A1
PL376756A1 PL376756A PL37675604A PL376756A1 PL 376756 A1 PL376756 A1 PL 376756A1 PL 376756 A PL376756 A PL 376756A PL 37675604 A PL37675604 A PL 37675604A PL 376756 A1 PL376756 A1 PL 376756A1
Authority
PL
Poland
Prior art keywords
carbamazepine
anxiety
dihydro
hydroxy
treatment
Prior art date
Application number
PL376756A
Other languages
English (en)
Inventor
Graeme Bilbe
John F. Cryan
Conrad Gentsch
Kevin Hall Mcallister
Markus Schmutz
Annick Vassout
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303613A external-priority patent/GB0303613D0/en
Priority claimed from GB0303614A external-priority patent/GB0303614D0/en
Priority claimed from GB0307281A external-priority patent/GB0307281D0/en
Priority claimed from GB0307278A external-priority patent/GB0307278D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL376756A1 publication Critical patent/PL376756A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL376756A 2003-02-17 2004-02-16 Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych PL376756A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0303613A GB0303613D0 (en) 2003-02-17 2003-02-17 Use of organic compounds
GB0303614A GB0303614D0 (en) 2003-02-17 2003-02-17 Use of organic compounds
GB0307281A GB0307281D0 (en) 2003-03-28 2003-03-28 Use of organic compounds
GB0307278A GB0307278D0 (en) 2003-03-28 2003-03-28 Use of organic compounds

Publications (1)

Publication Number Publication Date
PL376756A1 true PL376756A1 (pl) 2006-01-09

Family

ID=32872853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376756A PL376756A1 (pl) 2003-02-17 2004-02-16 Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych

Country Status (10)

Country Link
US (2) US7638510B2 (pl)
EP (1) EP1596866A2 (pl)
JP (1) JP2006517941A (pl)
AU (1) AU2004212328B2 (pl)
BR (1) BRPI0407569A (pl)
CA (1) CA2514649A1 (pl)
MX (1) MXPA05008729A (pl)
PL (1) PL376756A1 (pl)
TW (1) TW200507853A (pl)
WO (1) WO2004071152A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
KR101236227B1 (ko) * 2005-05-06 2013-02-21 바이알 - 포르텔라 앤드 씨에이 에스에이 에스리카르바제핀 아세테이트 및 그의 사용방법
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
CA2651954C (en) * 2006-05-11 2014-02-25 Academia Sinica Hla alleles associated with adverse drug reactions and methods for detecting such
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2747770A1 (en) * 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
JP2016047838A (ja) * 2015-11-05 2016-04-07 バイアル−ポルテラ アンド シーエー，エス．エー． 酢酸エスリカルバゼピン及び使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
DE60228988D1 (de) * 2001-11-12 2008-10-30 Novartis Ag Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen

Also Published As

Publication number Publication date
MXPA05008729A (es) 2005-09-20
WO2004071152A2 (en) 2004-08-26
CA2514649A1 (en) 2004-08-26
AU2004212328A1 (en) 2004-08-26
AU2004212328B2 (en) 2008-01-17
US20060194791A1 (en) 2006-08-31
US20100063029A1 (en) 2010-03-11
WO2004071152A3 (en) 2004-10-14
JP2006517941A (ja) 2006-08-03
EP1596866A2 (en) 2005-11-23
BRPI0407569A (pt) 2006-02-14
TW200507853A (en) 2005-03-01
US7638510B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
AU2003286567A8 (en) Methods for the treatment of skin disorders
HK1091732A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
PL1656346T3 (pl) 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
EP1578719A4 (en) P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
GB0417749D0 (en) Improved bipolar MOSFET devices and methods for their use
IL178827A0 (en) Use of reboxetine for the treatment of pain
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
IL175303A0 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
IL174303A0 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
EP1581206A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH 2,3-BENZODIAZEPINES
PL1670482T5 (pl) Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
PL376756A1 (pl) Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP1697536A4 (en) NEW OLIGONUCLEOTIDES AND TREATMENT OF HEART DISEASES USING THEREOF
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)